FR Regulatory | 7 October 2025 08:00
BROADPEAK SA
Press release – For immediate release October 6, 2025 – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2025
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Sophia Antipolis, France
(*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com .
Contacts
Regulatory filing PDF file File: 20251007 – BPK _ CP _ DDV au 01-10-2025 |
|
|
Language: | English |
Company: | BROADPEAK SA |
15 rue Claude Chappe | |
35510 CESSON SEVIGNE | |
France | |
Phone: | 02 22 74 03 50 |
Internet: | https://broadpeak.tv/ |
ISIN: | FR001400AJZ7 |
Euronext Ticker: | ALBPK |
AMF Category: | Total number of voting rights and share capital / Information on the total number of voting rights and the number of shares making up the share capital |
EQS News ID: | 2208772 |
End of Announcement | EQS News Service |
|
2208772 07-Oct-2025 CET/CEST